{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:05:45Z","timestamp":1789571145965,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Science and Technology Department of Jilin Province","award":["20250601002RC"],"award-info":[{"award-number":["20250601002RC"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although minocycline is a multi-target neuroprotective drug, its potential benefit in patients with ICH remains unclear. This study primarily aims to assess the efficacy and safety of minocycline for the treatment of ICH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Efficacy and Safety of Minocycline in the Treatment of ICH (ENHANCE) is an ongoing prospective, multicentre, randomised, open-label, blinded-endpoint clinical trial. A total of 1248 patients with ICH within 24\u00a0h of onset will be randomly assigned to the minocycline or control group at a ratio of 1:1. The minocycline group will receive an initial dose of 200\u00a0mg minocycline hydrochloride capsules in addition to the guideline-based treatment, followed by 100\u00a0mg orally every 12\u00a0h for 7\u00a0days, resulting in a total of 14 administrations. The control group will receive only the guideline-based treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study endpoints<\/jats:title>\n                    <jats:p>The primary efficacy outcome measure will be the proportion of patients with good functional outcomes (mRS score, 0\u20132) at 180\u00a0days. Safety outcome measures will include all adverse events and severe adverse events occurring during the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The ENHANCE trial is designed to evaluate the effectiveness and safety of minocycline in the treatment of ICH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Chinese Clinical Trials Registry identifier: ChiCTR2500114607.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/esj\/aakag084","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:31:45Z","timestamp":1789569105000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial"],"prefix":"10.1093","volume":"11","author":[{"given":"Yang","family":"Qu","sequence":"first","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Ni","family":"Guo","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]},{"name":"Neuroscience Research Center, Department of Neurology, The First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Qi","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reziya","family":"Abuduxukuer","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Li","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ni","family":"Lv","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Xin","family":"Xu","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-8522","authenticated-orcid":false,"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Stroke Center, Department of Neurology, the First Hospital of Jilin University , Changchun ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091610313503900_ref1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"23","author":"Collaborators GBDSRF","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026091610313503900_ref2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/bc.bc_177_24","article-title":"Advances in intracerebral hemorrhage management: a comprehensive review","volume":"12","author":"Wang","year":"2026","journal-title":"Brain Circ"},{"key":"2026091610313503900_ref3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/23969873251340815","article-title":"European Stroke Organisation (ESO) and European Association of Neurosurgical Societies (EANS) guideline on stroke due to spontaneous intracerebral haemorrhage","volume":"10","author":"Steiner","year":"2025","journal-title":"Eur Stroke J"},{"key":"2026091610313503900_ref4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1474-4422(25)00160-7","article-title":"Effects of blood pressure lowering in relation to time in acute intracerebral haemorrhage: a pooled analysis of the four interact trials","volume":"24","author":"Wang","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026091610313503900_ref5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0140-6736(24)00702-5","article-title":"Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial","volume":"403","author":"Beck","year":"2024","journal-title":"Lancet"},{"key":"2026091610313503900_ref6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(19)30195-3","article-title":"Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial","volume":"393","author":"Hanley","year":"2019","journal-title":"Lancet"},{"key":"2026091610313503900_ref7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-023-00424-7","article-title":"Intracerebral haemorrhage","volume":"9","author":"Puy","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"2026091610313503900_ref8","doi-asserted-by":"publisher","first-page":"e209714","DOI":"10.1212\/WNL.0000000000209714","article-title":"Surgical management for primary intracerebral hemorrhage","volume":"103","author":"Morris","year":"2024","journal-title":"Neurology"},{"key":"2026091610313503900_ref9","doi-asserted-by":"publisher","first-page":"17562864211049208","DOI":"10.1177\/17562864211049208","article-title":"Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage","volume":"14","author":"Bautista","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026091610313503900_ref10","first-page":"9","article-title":"Minocycline (minocin)","volume":"14","year":"1972","journal-title":"Med Lett Drugs Ther"},{"key":"2026091610313503900_ref11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/glia.2300","article-title":"Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor","volume":"64","author":"Moller","year":"2016","journal-title":"Glia"},{"key":"2026091610313503900_ref12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(25)01862-8","article-title":"Efficacy and safety of minocycline in patients with acute ischaemic stroke (emphasis): a multicentre, double-blind, randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"key":"2026091610313503900_ref13","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001","article-title":"Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia","volume":"21","author":"Tikka","year":"2001","journal-title":"J Neurosci"},{"key":"2026091610313503900_ref14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/brainsci13030512","article-title":"Minocycline attenuates sevoflurane-induced postoperative cognitive dysfunction in aged mice by suppressing hippocampal apoptosis and the notch signaling pathway-mediated neuroinflammation","author":"Liang","year":"2023","journal-title":"Brain Sci"},{"key":"2026091610313503900_ref15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.brainres.2005.02.062","article-title":"Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage","volume":"1044","author":"Morimoto","year":"2005","journal-title":"Brain Res"},{"key":"2026091610313503900_ref16","doi-asserted-by":"publisher","first-page":"136297","DOI":"10.1016\/j.neulet.2021.136297","article-title":"Neuroprotection of minocycline by inhibition of extracellular matrix metalloproteinase inducer expression following intracerebral hemorrhage in mice","volume":"764","author":"Liu","year":"2021","journal-title":"Neurosci Lett"},{"key":"2026091610313503900_ref17","doi-asserted-by":"publisher","first-page":"844163","DOI":"10.3389\/fimmu.2022.844163","article-title":"Revisiting minocycline in intracerebral hemorrhage: mechanisms and clinical translation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026091610313503900_ref18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/STROKEAHA.117.019860","article-title":"Minocycline effects on intracerebral hemorrhage-induced iron overload in aged rats: brain iron quantification with magnetic resonance imaging","volume":"49","author":"Cao","year":"2018","journal-title":"Stroke"},{"key":"2026091610313503900_ref19","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2026091610313503900_ref20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/jhm.13051","article-title":"Clinical guideline highlights for the hospitalist: 2022 American Heart Association\/American Stroke Association guideline for the management of patients with spontaneous intracerebral hemorrhage","volume":"18","author":"Burroughs-Ray","year":"2023","journal-title":"J Hosp Med"},{"key":"2026091610313503900_ref21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/23969873231201712","article-title":"Safety and efficacy of remote ischemic conditioning for spontaneous intracerebral hemorrhage (SERIC-ICH): a multicenter, randomized, parallel-controlled clinical trial study design and protocol","volume":"9","author":"Guo","year":"2024","journal-title":"Eur Stroke J"},{"key":"2026091610313503900_ref22","doi-asserted-by":"publisher","first-page":"103900","DOI":"10.1016\/j.eclinm.2026.103900","article-title":"Remote ischaemic conditioning in patients with supratentorial intracerebral haemorrhage (RICH-2): a multicentre, randomised, sham-controlled phase 3 trial in China","volume":"95","author":"Zhao","year":"2026","journal-title":"EClinicalMedicine"},{"key":"2026091610313503900_ref23","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1161\/STROKEAHA.113.000780","article-title":"Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis","volume":"44","author":"Kohler","year":"2013","journal-title":"Stroke"},{"key":"2026091610313503900_ref24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S1474-4422(19)30069-9","article-title":"Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial","volume":"18","author":"Selim","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026091610313503900_ref25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/pst.1743","article-title":"A win ratio approach to comparing continuous non-normal outcomes in clinical trials","volume":"15","author":"Wang","year":"2016","journal-title":"Pharm Stat"},{"key":"2026091610313503900_ref26","doi-asserted-by":"publisher","first-page":"O47","DOI":"10.1186\/1745-6215-14-S1-O47","article-title":"A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials","volume":"14","author":"Wang","year":"2013","journal-title":"Trials"},{"key":"2026091610313503900_ref27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1128\/AAC.44.3.763-766.2000","article-title":"Iron-chelating activity of tetracyclines and its impact on the susceptibility of Actinobacillus actinomycetemcomitans to these antibiotics","volume":"44","author":"Grenier","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091610313503900_ref28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/svn-2020-000334","article-title":"Intracerebral haemorrhage: from clinical settings to animal models","volume":"5","author":"Bai","year":"2020","journal-title":"Stroke Vasc Neurol"},{"key":"2026091610313503900_ref29","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1161\/STROKEAHA.117.018658","article-title":"Minocycline in acute cerebral hemorrhage: an early phase randomized trial","volume":"48","author":"Fouda","year":"2017","journal-title":"Stroke"},{"key":"2026091610313503900_ref30","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/ene.13403","article-title":"Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study","volume":"24","author":"Chang","year":"2017","journal-title":"Eur J Neurol"},{"key":"2026091610313503900_ref31","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1161\/01.STR.0000103140.52838.45","article-title":"Iron and iron-handling proteins in the brain after intracerebral hemorrhage","volume":"34","author":"Wu","year":"2003","journal-title":"Stroke"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/9\/aakag084\/71123437\/aakag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/11\/9\/aakag084\/71123437\/aakag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:31:46Z","timestamp":1789569106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/doi\/10.1093\/esj\/aakag084\/8802157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/esj\/aakag084","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9]]},"article-number":"aakag084"}}